Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management.

FeNO after three months showed a significant reduction (median FeNO pre 32, IQR 19-48.5 vs median FeNO post 19, IQR 16.5-26) ( Figure 1c ), while we observed a relative increase in eosinophils blood count, despite it did not reach statistical significance and no clinical impact (median eosinophils pre 280, IQR 193.8-647.3 vs median eosinophils post 349.5, IQR 103-836.8; p=0.52) ( Figure 1d ).

also in 111,027 other papers